YONGIN, South Korea, Nov. 27, 2025 — GC Genome, a prominent company specializing in clinical genomics and liquid biopsy, has announced the publication of its joint research with Professor Byeon, Jeong-Sik’s team from Asan Medical Center in The American Journal of Gastroenterology (AJG).
GC Genome utilized its exclusive AI-driven fragmentomics technology, which is incorporated in its MCED test, ai-CANCERCH. The study highlights the potential for a user-friendly alternative to colonoscopies and stool-based screening methods, facilitating the early detection of colorectal cancer and advanced adenomas.
Study Overview
- A total of 1,677 participants were enrolled, including 302 with CRC and 108 with AA.
- 1,267 participants with normal colonoscopy results served as healthy or non-cancer controls.
The test assesses cfDNA fragmentomic signatures using low-coverage whole-genome sequencing (Lc-WGS) along with a unique AI algorithm, enabling highly sensitive detection of early-stage disease.
Key Findings
- CRC sensitivity: 90.4%
- Specificity in individuals with normal colonoscopy results: 94.7%
- Sensitivities by CRC stage: 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV)
- Sensitivity for T1N0 lesions (suitable for endoscopic resection): 90.0%
- Sensitivity for AA: 58.3%
The results remained consistent across different CRC locations (left vs. right colon), age groups of CRC patients (<60 vs. ≥60), and AA locations.
These findings underscore the test’s potential as a dependable cfDNA-based blood test for CRC screening and early prevention.
According to a GC Genome spokesperson, “The ability to detect colorectal cancer along with precancerous lesions marks a significant advancement in prevention. With our fragmentomics technology now validated through publication in a leading gastroenterology journal, GC Genome will continue to broaden its global clinical collaborations and screening applications.”
About ai-CANCERCH
Launched in September 2023, ai-CANCERCH is an AI-based multi-cancer early detection (MCED) test powered by Lc-WGS. Using only 10 mL of blood, the test identifies signals related to multiple cancers. A major upgrade, expanding from 6 detectable cancers to 10 cancers (colorectal, lung, esophageal, liver, ovarian, pancreatic, biliary, breast, gastric, and head-and-neck), is scheduled for January 2026.
About GC Genome
GC Genome is a leading diagnostics firm committed to connecting care and cure globally by providing genetic diagnosis services for Oncology, Pre&Neonatal, Rare Diseases, and Health Check-ups, and by suggesting personalized treatments for longer, healthier lives. Established in 2013 as a GC company, GC Genome operates a CAP-accredited laboratory and prioritizes R&D. With strong partnerships established worldwide, GC Genome has demonstrated impressive growth, continually expanding its testing capabilities.
GC Genome Contacts (Media)
Sohee Kim
Yelin Jun
Yoonjae Na
SOURCE GC Genome